PHS
AVDL

Pekin Hardy Strauss’s Avadel Pharmaceuticals AVDL Stock Holding History

Pekin Hardy Strauss’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,000
Closed -$110K – 366
2025
Q1 		$110K Buy
+14,000
New +$117K 0.01% 346

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pekin Hardy Strauss's AVDL Position: Q2 2025 in Review

Pekin Hardy Strauss sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 14,000 shares — an estimated $110K sold.

Pekin Hardy Strauss first reported a position in AVDL in Q1 2025 and held it in 1 quarter. The position peaked at $110K in Q1 2025. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Pekin Hardy Strauss reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Pekin Hardy Strauss sold 14,000 Avadel Pharmaceuticals shares in Q2 2025, an estimated $110K.
  • Pekin Hardy Strauss first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Pekin Hardy Strauss's Avadel Pharmaceuticals position peaked at $110K in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Pekin Hardy Strauss's 13F filing for Q2 2025, filed 6 Aug 2025.